Inclusion:

          -  Patient resectable muscle-invasive bladder cancer with clinical stage T2-T4aN0/1M0
             with transitional and mixed transitional cell histology

          -  Patients must be planning to undergo a radical cystectomy

          -  Patients who have not received prior systemic chemotherapy or immunotherapy for
             treatment of MIBC

          -  ECOG performance status of 0 or 1

          -  Must have a life expectancy of at least 12 weeks at randomization

        Exclusion:

          -  Evidence of lymph node (N2-N3) or metastatic (M1) disease at time of screening.

          -  Prior pelvic radiotherapy treatment within 2 years of randomization to study

          -  Prior exposure to immune-mediated therapy (with exclusion of Bacillus-Calmette Guerin
             [BCG]), including but not limited to other anti-CTLA-4, anti-PD-1, anti PD-L1, or
             anti-PD-L2 antibodies.

          -  Current or prior use of immunosuppressive medication within 14 days before the first
             dose of investigational product (IP). The following are exceptions to this criterion:
             Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra
             articular injection); Systemic corticosteroids at physiologic doses not to exceed 10
             mg/day of prednisone or its equivalent; Steroids as premedication for hypersensitivity
             reactions (eg, CT scan premedication)

          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.

          -  Uncontrolled intercurrent illness

          -  Active infection including Tuberculosis, Hepatitis B, Hepatitis C, and Human
             Immunodeficiency